Objective To determine whether the combined use of glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT-2) inhibitors is associated with a decreased risk of major adverse cardiovascular events and serious renal events compared with either drug class alone among patients with type 2 diabetes, and to assess the effect of the combination on the individual components of major adverse cardiovascular events, heart failure, and all cause mortality.
Design Population based cohort study using a prevalent new-user design, emulating a trial.
Setting UK Clinical Practice Research Datalink linked to Hospital Episode Statistics Admitted Patient Care and Office for National Statistics databases.
Participants Two prevalent new-user cohorts were assembled between January 2013 and December 2020, with follow-up until the end of March 2021. The first cohort included 6696 patients who started GLP-1 receptor agonists and added on SGLT-2 inhibitors, and the second inc
NewCa.com: JOBS 🧑🔎⚕️ The Toxicity of Beauty Products Under the newca.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newca.com Daily Mail and Mail on Sunday newspapers.
A Windsor program that helps connect cancer patients to clinical trials is now planning to expand after receiving its first national grant. The Clinical Trials Navigator program, founded by Caroline Hamm, helps people with cancer find alternative and experimental treatments by connecting them to clinical trials that they are eligible for. The program was also developed alongside former Windsor Regional Hospital board chair and cancer patient Ron Truant."What we do is we navigate a system that is
"We will all profit from a more diverse, inclusive society, understanding, accommodating, even celebrating our differences, while pulling together for the
Among 10 patients evaluated, compared with their baseline at 1 week after receiving their final dose in the trial, 30% demonstrated clinical improvement on the Alzheimer’s disease composite score.